JP2001525814A - グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 - Google Patents
グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物Info
- Publication number
- JP2001525814A JP2001525814A JP54879998A JP54879998A JP2001525814A JP 2001525814 A JP2001525814 A JP 2001525814A JP 54879998 A JP54879998 A JP 54879998A JP 54879998 A JP54879998 A JP 54879998A JP 2001525814 A JP2001525814 A JP 2001525814A
- Authority
- JP
- Japan
- Prior art keywords
- lysozyme
- glycyrrhizic acid
- lactoferrin
- protein
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 32
- 239000001685 glycyrrhizic acid Substances 0.000 title claims abstract description 32
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims abstract description 32
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 title claims abstract description 31
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims abstract description 31
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 235000019410 glycyrrhizin Nutrition 0.000 title claims abstract description 31
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims description 12
- 239000003443 antiviral agent Substances 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 38
- 108010014251 Muramidase Proteins 0.000 claims description 35
- 102000016943 Muramidase Human genes 0.000 claims description 35
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 35
- 229960000274 lysozyme Drugs 0.000 claims description 35
- 239000004325 lysozyme Substances 0.000 claims description 35
- 102000010445 Lactoferrin Human genes 0.000 claims description 20
- 108010063045 Lactoferrin Proteins 0.000 claims description 20
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 20
- 235000021242 lactoferrin Nutrition 0.000 claims description 20
- 229940078795 lactoferrin Drugs 0.000 claims description 20
- 241000287828 Gallus gallus Species 0.000 claims description 19
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 7
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 229940072440 bovine lactoferrin Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 17
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 102000050459 human LTF Human genes 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000003602 anti-herpes Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000948258 Gila Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97A001119 | 1997-05-14 | ||
| IT97MI001119A IT1291366B1 (it) | 1997-05-14 | 1997-05-14 | Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale |
| PCT/EP1998/002797 WO1998051334A1 (en) | 1997-05-14 | 1998-05-06 | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008331229A Division JP2009102370A (ja) | 1997-05-14 | 2008-12-25 | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001525814A true JP2001525814A (ja) | 2001-12-11 |
Family
ID=11377123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54879998A Ceased JP2001525814A (ja) | 1997-05-14 | 1998-05-06 | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
| JP2008331229A Ceased JP2009102370A (ja) | 1997-05-14 | 2008-12-25 | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008331229A Ceased JP2009102370A (ja) | 1997-05-14 | 2008-12-25 | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6329339B1 (https=) |
| EP (1) | EP0980254B1 (https=) |
| JP (2) | JP2001525814A (https=) |
| KR (1) | KR100592193B1 (https=) |
| CN (1) | CN1114447C (https=) |
| AR (1) | AR012849A1 (https=) |
| AT (1) | ATE212232T1 (https=) |
| AU (1) | AU740944B2 (https=) |
| BG (1) | BG64748B1 (https=) |
| CA (1) | CA2289550A1 (https=) |
| CZ (1) | CZ291932B6 (https=) |
| DE (1) | DE69803565T2 (https=) |
| DK (1) | DK0980254T3 (https=) |
| EA (1) | EA003126B1 (https=) |
| ES (1) | ES2170501T3 (https=) |
| GE (1) | GEP20022672B (https=) |
| HU (1) | HU224956B1 (https=) |
| IL (2) | IL132651A0 (https=) |
| IT (1) | IT1291366B1 (https=) |
| PL (1) | PL189218B1 (https=) |
| PT (1) | PT980254E (https=) |
| SK (1) | SK283584B6 (https=) |
| TR (1) | TR199902730T2 (https=) |
| UA (1) | UA63955C2 (https=) |
| WO (1) | WO1998051334A1 (https=) |
| ZA (1) | ZA983917B (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019506460A (ja) * | 2016-02-25 | 2019-03-07 | アプライド バイオロジカル ラボラトリーズ インコーポレイテッド | 浮遊病原体および刺激物に対して防御するための組成物および方法 |
| JP2022533876A (ja) * | 2020-04-27 | 2022-07-27 | 広州新創憶薬物臨床研究有限公司 | Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 |
| JP2023517771A (ja) * | 2020-04-27 | 2023-04-26 | 広州新創憶薬物臨床研究有限公司 | 抗新型コロナウイルス感染症の医薬品、食品、及び使用 |
| US12594285B2 (en) | 2016-02-25 | 2026-04-07 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| WO2003088914A2 (en) * | 2002-04-18 | 2003-10-30 | The University Of Iowa Research Foundation | Methods of inhibiting and treating bacterial biofilms by metal chelators |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| WO2007076200A2 (en) * | 2005-11-28 | 2007-07-05 | Medimmune, Inc. | Antagonists of hmgb1 and/or rage and methods of use thereof |
| IT1391170B1 (it) * | 2008-08-07 | 2011-11-18 | D M G Italia S R L | Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale |
| US9416151B2 (en) | 2010-08-25 | 2016-08-16 | Lurong ZHANG | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| WO2012026928A1 (en) * | 2010-08-25 | 2012-03-01 | Diacarta Llc | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| EP3108894B1 (en) | 2014-02-21 | 2022-01-26 | Kewpie Corporation | Non-therapeutic method of deactivating norovirus, use of lysozyme component for non-therapeutic norovirus deactivation, and lysozyme component for use in the prevention or treatment of norovirus infection |
| US12447166B2 (en) | 2016-02-25 | 2025-10-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| CN109022351B (zh) * | 2018-09-28 | 2021-10-19 | 广州奇龙生物科技有限公司 | 重组人溶菌酶的新应用 |
| MX2021005280A (es) * | 2021-05-04 | 2022-02-23 | Spv Timser S A P I De C V | Composicion farmaceutica que contiene triterpenoides pentaciclicos. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085800B2 (ja) * | 1986-12-19 | 1996-01-24 | エーザイ株式会社 | 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤 |
| JP2838720B2 (ja) * | 1989-10-31 | 1998-12-16 | ゼリア新薬工業株式会社 | 安定な点眼剤 |
| JP4056099B2 (ja) * | 1996-05-09 | 2008-03-05 | 森永乳業株式会社 | 水生動物の寄生生物性疾患の予防および治療剤 |
-
1997
- 1997-05-14 IT IT97MI001119A patent/IT1291366B1/it active IP Right Grant
-
1998
- 1998-05-06 IL IL13265198A patent/IL132651A0/xx active IP Right Grant
- 1998-05-06 EP EP98925588A patent/EP0980254B1/en not_active Expired - Lifetime
- 1998-05-06 AT AT98925588T patent/ATE212232T1/de not_active IP Right Cessation
- 1998-05-06 KR KR1019997010372A patent/KR100592193B1/ko not_active Expired - Fee Related
- 1998-05-06 DK DK98925588T patent/DK0980254T3/da active
- 1998-05-06 CZ CZ19993991A patent/CZ291932B6/cs not_active IP Right Cessation
- 1998-05-06 DE DE69803565T patent/DE69803565T2/de not_active Expired - Fee Related
- 1998-05-06 SK SK1544-99A patent/SK283584B6/sk not_active IP Right Cessation
- 1998-05-06 PT PT98925588T patent/PT980254E/pt unknown
- 1998-05-06 PL PL98336802A patent/PL189218B1/pl not_active IP Right Cessation
- 1998-05-06 HU HU0002985A patent/HU224956B1/hu not_active IP Right Cessation
- 1998-05-06 CA CA002289550A patent/CA2289550A1/en not_active Abandoned
- 1998-05-06 GE GEAP19985126A patent/GEP20022672B/en unknown
- 1998-05-06 AU AU77646/98A patent/AU740944B2/en not_active Ceased
- 1998-05-06 WO PCT/EP1998/002797 patent/WO1998051334A1/en not_active Ceased
- 1998-05-06 US US09/423,611 patent/US6329339B1/en not_active Expired - Fee Related
- 1998-05-06 JP JP54879998A patent/JP2001525814A/ja not_active Ceased
- 1998-05-06 TR TR1999/02730T patent/TR199902730T2/xx unknown
- 1998-05-06 EA EA199901024A patent/EA003126B1/ru not_active IP Right Cessation
- 1998-05-06 ES ES98925588T patent/ES2170501T3/es not_active Expired - Lifetime
- 1998-05-06 CN CN98805037A patent/CN1114447C/zh not_active Expired - Fee Related
- 1998-05-08 ZA ZA983917A patent/ZA983917B/xx unknown
- 1998-05-13 AR ARP980102218A patent/AR012849A1/es active IP Right Grant
- 1998-06-05 UA UA99126790A patent/UA63955C2/uk unknown
-
1999
- 1999-10-29 IL IL132651A patent/IL132651A/en not_active IP Right Cessation
- 1999-12-08 BG BG103968A patent/BG64748B1/bg unknown
-
2008
- 2008-12-25 JP JP2008331229A patent/JP2009102370A/ja not_active Ceased
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019506460A (ja) * | 2016-02-25 | 2019-03-07 | アプライド バイオロジカル ラボラトリーズ インコーポレイテッド | 浮遊病原体および刺激物に対して防御するための組成物および方法 |
| JP7071933B2 (ja) | 2016-02-25 | 2022-05-19 | アプライド バイオロジカル ラボラトリーズ インコーポレイテッド | 浮遊病原体および刺激物に対して防御するための組成物および方法 |
| JP2022115999A (ja) * | 2016-02-25 | 2022-08-09 | アプライド バイオロジカル ラボラトリーズ インコーポレイテッド | 浮遊病原体および刺激物に対して防御するための組成物および方法 |
| JP7458438B2 (ja) | 2016-02-25 | 2024-03-29 | アプライド バイオロジカル ラボラトリーズ インコーポレイテッド | 浮遊病原体および刺激物に対して防御するための組成物および方法 |
| US12447200B2 (en) | 2016-02-25 | 2025-10-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| US12594285B2 (en) | 2016-02-25 | 2026-04-07 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| JP2022533876A (ja) * | 2020-04-27 | 2022-07-27 | 広州新創憶薬物臨床研究有限公司 | Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 |
| JP2023517771A (ja) * | 2020-04-27 | 2023-04-26 | 広州新創憶薬物臨床研究有限公司 | 抗新型コロナウイルス感染症の医薬品、食品、及び使用 |
| JP7399976B2 (ja) | 2020-04-27 | 2023-12-18 | 広州新創憶薬物臨床研究有限公司 | Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 |
| JP7543427B2 (ja) | 2020-04-27 | 2024-09-02 | 広州新創憶薬物臨床研究有限公司 | 抗新型コロナウイルス感染症の医薬品、食品、及び使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001525814A (ja) | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 | |
| Weinberg | Iron withholding: a defense against viral infections | |
| CN111529685A (zh) | 抗呼吸道病毒感染的鼻腔喷雾制剂 | |
| Lampis et al. | Enhancement of anti-herpetic activity of glycyrrhizic acid by physiological proteins | |
| JP2003505419A (ja) | ケトチフェンを含む眼用組成物 | |
| CN111658664A (zh) | 海参多糖在抗新型冠状病毒中的应用 | |
| WO2023232095A1 (zh) | 一种基于病毒阻断剂的口腔喷雾制剂及其用途 | |
| KR101400379B1 (ko) | 안정하고 여과 가능한 외피보유 바이러스 조성물 | |
| JP2025166032A (ja) | 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 | |
| KR102538216B1 (ko) | 폴리감마글루탐산을 유효성분으로 포함하는 코로나바이러스(SARS-CoV-2) 감염질환의 예방, 경감 또는 치료용 약학적 조성물 | |
| JPS61286325A (ja) | 後天的免疫不全症の治療剤 | |
| JP2023524911A5 (https=) | ||
| CA2374681A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| EP1075270B1 (en) | Short peptide for treatment of neurological degenerative diseases | |
| MXPA99010447A (en) | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity | |
| HU193217B (en) | Process for producing active agents for immunemodulator compositions | |
| HK1028347B (en) | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity | |
| JPH02233619A (ja) | ウィルス感染防御剤 | |
| EP0360191A2 (en) | Anti-aids virus composition | |
| CN117018034A (zh) | 胎盘源细胞因子在治疗和预防疱疹病毒感染及其相关疾病的应用 | |
| KR20220041003A (ko) | 니클로사마이드를 포함하는 항-메르스 코로나바이러스 조성물 | |
| Rodu et al. | In vitro virucidal activity components of a forming medication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080902 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090130 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090305 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090317 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20090728 |